Atabey Lab. on Cancer Biology and Signaling

Overview

Atabey Lab. has been working in the field of Cancer Biology and Signaling. The scientific goal of our group is to fill the gaps in the fundamental biological mechanisms underlying the development and progression of cancer. Over the past two decades, our group has been working on to develop deeper understanding the role of signal transduction cascade in cancer development and progression and using this molecular knowledge to improve the diagnosis and treatment of cancer.

Specific Goals

1) Identification of the potential reciprocal crosstalk between c-Met receptor and other signaling molecules and their cooperative interaction in drug resistance in HCC
2) Investigating HGF/c-Met axis in tumor microenvironment and metastasis formation in the liver
3) Identification of the potential reciprocal crosstalk between HGF/c-Met signaling and glucose metabolism in HCC using various in vitro and in vivo models and further use this knowledge for developing strategies to prevent HCC
4) Identification of the roles of non-coding RNAs in the regulation of c-Met signaling in HCC
5) Deciphering signaling pathways in clinical samples for precision medicine using omics technologies
6) The use of omics data obtaining by our group and by the literature to investigate signaling mechanisms in metastasis and cancer by using in silico methods
7) Fabrication and validation of Lab-on-a-chip (LOC) system to predict metastatic and invasive ability to circulating tumor cells
8) Application of LOC in the early stage of anti-metastatic drug discovery focusing on gene expressions, receptor signaling and susceptibility

Our Team

Peyda Korhan, Research Associate

BSc (1998-2002); Thrace University, Biology

MSc (2003-2005); University of Wolverhampton UK, Biomedical Science

PhD (2007- 2014); Dokuz Eylül University, Medical Biology and Genetics

Yasemin Öztemur Islakoğlu, Post-Doctoral Researcher

BSc (2007-2011); Hacettepe University, Biology

MSc (2011-2013); Ankara University Biotechnology Institute, Basic Biotechnology

PhD (2014-2018); Ankara University Biotechnology Institute, Basic Biotechnology

Yeliz Yılmaz, PhD Candidate

BSc (2004-2008); Boğaziçi University, Molecular Biology and Genetics

MSc (2008-2011); Boğaziçi University, Molecular Biology and Genetics

Ezgi Bağırsakçı, PhD Candidate

BSc (2009 – 2014); İhsan Doğramacı Bilkent University, Molecular Biology and Genetics

MSc (2015-2017); Dokuz Eylül University, Medical Biology and Genetics

Dehan Çömez, PhD Candidate​​​​​​​

BSc (2010-2014); İstanbul University, Molecular Biology and Genetics

MSc (2016-2019); Dokuz Eylül University, Izmir International Biomedicine and Genome Institute, Molecular Biology and Genetics

Gülsün Bağcı, PhD Candidate​​​​​​​

BSc (2012-2016); Izmir Institute of Technology (IZTECH), Molecular Biology and Genetics

MSc (2016-2019); Dokuz Eylül University, Izmir International Biomedicine and Genome Institute, Molecular Biology and Genetics

Alumni

Ayşim Güneş, PhD

Thesis: The Role of Signaling Pathways Associated with Oxidative Stress in the Progression of Hepatocellular Carcinoma

Current Position: Post-Doctoral Researcher, Montreal Clinical Research Institute (IRCM), McGill University

Erkan Kahraman, PhD

Thesis: Investigation of the Role of Sestrin 2 in Progression of Hepatocellular Carcinoma

Current Position: Assistant Professor, Atatürk Health Care Vocational School, Ege University

Hande Topel, PhD

Thesis: Investigation of the Relationship of c-Met Signalization and lncRNA HOTAIR in Epithelial-to-Mesenchymal
Transition Process of Hepatocellular Carcinoma

Current Position: Post-Doctoral Researcher, University of Southern Denmark (SDU)

Group Members

Atabey Lab. on Cancer Biology and Signaling

Group Leader

Neşe ATABEY
nese.atabey@ibg.edu.tr
+90 232 299 41 00 (5221)
+9 02322994172

Peyda KORHAN Researcher  peyda.korhan@ibg.edu.tr


Yeliz YILMAZ Research Assistant  yeliz.yilmaz@ibg.edu.tr


Ezgi BAĞIRSAKÇI Ph.D. Student  ezgi.bagirsakci@msfr.ibg.edu.tr


Gülsün BAĞCI MSc Student  gulsun.bagci@msfr.ibg.edu.tr


Yasemin ÖZTEMUR Post-doc Researcher  yasemin.oztemur@ibg.edu.tr


Dehan ÇÖMEZ Ph.D. Student  dehan.comez@ibg.edu.tr


Selected Publications

Aysim Gunes, Ezgi Bagirsakci, Evin Iscan, Gulcin Cakan-Akdogan, Umut Aykutlu, Serif Senturk, Gunes Ozhan, Esra Erdal, Deniz Nart, Funda Yilmaz Barbet, Nese Atabey. Thioredoxin interacting protein promotes invasion in hepatocellular carcinoma. Oncotarget. 2018 ; 9 (96): 36849-36866. doi:10.18632/oncotarget.26402.

İşcan E, Güneş A, Korhan P, Yılmaz Y, Erdal E, Atabey N. The regulatory role of heparin on c-Met signaling in hepatocellular carcinoma cells. J Cell Commun Signal. 2017 June; 11 (2): 155-166. doi:10.1007/s12079-016-0368-0.

Firtina Karagonlar Z, Koç D, Şahin E, Avci ST, Yilmaz M, Atabey N, Erdal E. Effect of adipocyte-secreted factors on EpCAM+/CD133+ hepatic stem cell population.. Biochemical and biophysical research communications. 2016 January; 474 (3): 482-490. doi:10.1016/j.bbrc.2016.04.137.

Firtina Karagonlar Z, Koc D, Iscan E, Erdal E, Atabey N. Elevated hepatocyte growth factor expression as an autocrine c-Met activation mechanism in acquired resistance to sorafenib in hepatocellular carcinoma cells.. Cancer science. 2016 January; 107 (4): 407-16. doi:10.1111/cas.12891.

Gunes A, Iscan E, Topel H, Avci ST, Gumustekin M, Erdal E, Atabey N. Heparin treatment increases thioredoxin interacting protein expression in hepatocellular carcinoma cells.. The international journal of biochemistry & cell biology. 2015 January; 65: 169-81. doi:10.1016/j.biocel.2015.05.025.

Korhan P, Erdal E, Kandemiş E, Cokaklı M, Nart D, Yılmaz F, Can A, Atabey N. Reciprocal activating crosstalk between c-Met and caveolin 1 promotes invasive phenotype in hepatocellular carcinoma.. PloS one. 2014 January; 9 (8): e105278. doi:10.1371/journal.pone.0105278.

Korhan P, Erdal E, Atabey N. MiR-181a-5p is downregulated in hepatocellular carcinoma and suppresses motility, invasion and branching-morphogenesis by directly targeting c-Met.. Biochemical and biophysical research communications. 2014 January; 450 (4): 1304-12. doi:10.1016/j.bbrc.2014.06.142.

Kunter I, Erdal E, Nart D, Yilmaz F, Karademir S, Sagol O, Atabey N. Active form of AKT controls cell proliferation and response to apoptosis in hepatocellular carcinoma.. Oncology reports. 2014 January; 31 (2): 573-80. doi:10.3892/or.2013.2932.

Bozkaya G, Korhan P, Cokaklı M, Erdal E, Sağol O, Karademir S, Korch C, Atabey N. Cooperative interaction of MUC1 with the HGF/c-Met pathway during hepatocarcinogenesis.. Molecular cancer. 2012 January; 11: 64. doi:10.1186/1476-4598-11-64.

Gumustekin M, Kargi A, Bulut G, Gozukizil A, Ulukus C, Oztop I, Atabey N. HGF/c-Met overexpressions, but not met mutation, correlates with progression of non-small cell lung cancer.. Pathology oncology research : POR. 2012 January; 18 (2): 209-18. doi:10.1007/s12253-011-9430-7.

Ozen E, Gozukizil A, Erdal E, Uren A, Bottaro DP, Atabey N. Heparin inhibits Hepatocyte Growth Factor induced motility and invasion of hepatocellular carcinoma cells through early growth response protein 1.. PloS one. 2012 January; 7 (8): e42717. doi:10.1371/journal.pone.0042717.

Cokakli M, Erdal E, Nart D, Yilmaz F, Sagol O, Kilic M, Karademir S, Atabey N. Differential expression of Caveolin-1 in hepatocellular carcinoma: correlation with differentiation state, motility and invasion.. BMC cancer. 2009 January; 9: 65. doi:10.1186/1471-2407-9-65.

Total: 12

Projects

Tubitak - RD : METASTAZIN ERKEN TANISINDA YENİ BİR YONGA ÜSTÜ LABORATUVAR (LAB ON A CHIP; LOC) CİHAZI , None

Tubitak - RD : YÜKSEK GLUKOZ ARACILIKLI HEPATOSELLÜLER KARSİNOMA PROGRESYONUNUN MOLEKÜLER MEKANİZMASI: C-MET AKTİVASYONU VE YENİ ADAYLAR THİOREDOXİN INTERACTİNG PROTEİN, SESTRİN2, VE INCRNA HOTAIR , None

Contact

Atabey Lab. on Cancer Biology and Signaling

Group Leader

Neşe ATABEY
nese.atabey@ibg.edu.tr
+90 232 299 41 00 (5221)
+9 02322994172